yellowballs
New member
TB 500 does this:
Endothelial (blood vessels) cell differentiation
Angiogenesis (growth of new blood cells from pre-existing vessels) in dermal tissues
Keratinocyte migration
Collagen deposition; and
Decreases inflammation.
Angiogenesis is a normal and vital process in growth and development, as well as in wound healing and in granulation tissue. However, it is also a fundamental step in the transition of tumors from a dormant state to a malignant one, leading to the use of angiogenesis inhibitors. The identification of an angiogenic diffusible factor derived from tumors was made initially by Greenblatt and Shubik in 1968.
Also to add to this. Pharma companies apparently failed TB 500 as a drug because of this reason. Thats a little scary cause big pharma is not always shy about letting its customers pick up a few side effects from their drugs. So maybe this side effect from TB 500 is so common there was no way even they could justify it as a good drug?
further on it reads.............The progression of chronic and proliferative inflammation depends on angiogenesis (Jackson JR, et al.,
1997). It is required not only for the maintenance of tissue perfusion, but also to allow an increase in the
cellular traffic required for chronicity (Colville N, et al., 1995). Therefore, the inhibition of angiogenesis
would be a valid target for drug development in chronic inflammatory diseases such as rheumatoid
arthritis (Colville N, et al., 1992), atherosclerosis (Sueishi K, et al., 1997), diabetic retinopathy (Ishibashi
T, et al., 1999), psoriasis (Li VW, et al., 1996), wound healing (Suzuki N, et al., 1998 ), and chronic
airway inflammation (Thurston G, et al., 1998), as well as for antineoplastic therapy and Kaposi***8217;s
sarcoma (Folkman J, et al., 1995). Vascular endothelial growth factor (VEGF) is a potent inducer of
angiogenesis (Breier G, et al., 1992).
Endothelial (blood vessels) cell differentiation
Angiogenesis (growth of new blood cells from pre-existing vessels) in dermal tissues
Keratinocyte migration
Collagen deposition; and
Decreases inflammation.
Angiogenesis is a normal and vital process in growth and development, as well as in wound healing and in granulation tissue. However, it is also a fundamental step in the transition of tumors from a dormant state to a malignant one, leading to the use of angiogenesis inhibitors. The identification of an angiogenic diffusible factor derived from tumors was made initially by Greenblatt and Shubik in 1968.
Also to add to this. Pharma companies apparently failed TB 500 as a drug because of this reason. Thats a little scary cause big pharma is not always shy about letting its customers pick up a few side effects from their drugs. So maybe this side effect from TB 500 is so common there was no way even they could justify it as a good drug?
further on it reads.............The progression of chronic and proliferative inflammation depends on angiogenesis (Jackson JR, et al.,
1997). It is required not only for the maintenance of tissue perfusion, but also to allow an increase in the
cellular traffic required for chronicity (Colville N, et al., 1995). Therefore, the inhibition of angiogenesis
would be a valid target for drug development in chronic inflammatory diseases such as rheumatoid
arthritis (Colville N, et al., 1992), atherosclerosis (Sueishi K, et al., 1997), diabetic retinopathy (Ishibashi
T, et al., 1999), psoriasis (Li VW, et al., 1996), wound healing (Suzuki N, et al., 1998 ), and chronic
airway inflammation (Thurston G, et al., 1998), as well as for antineoplastic therapy and Kaposi***8217;s
sarcoma (Folkman J, et al., 1995). Vascular endothelial growth factor (VEGF) is a potent inducer of
angiogenesis (Breier G, et al., 1992).
